e0464181-da72-4a14-9039-a396843c39f2
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 57
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.640
- INTERFERON_GAMMA_RESPONSE+0.520
- MYC_TARGETS_V1+0.500
- OXIDATIVE_PHOSPHORYLATION+0.500
- E2F_TARGETS+0.480
- MTORC1_SIGNALING+0.410
- MYC_TARGETS_V2+0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.410
- ALLOGRAFT_REJECTION+0.400
- FATTY_ACID_METABOLISM+0.360
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.470
- HEDGEHOG_SIGNALING-0.440
- APICAL_JUNCTION-0.300
- ESTROGEN_RESPONSE_EARLY-0.290
- MYOGENESIS-0.280
- UV_RESPONSE_DN-0.270
- MITOTIC_SPINDLE-0.240
- APICAL_SURFACE-0.220
- ANGIOGENESIS-0.200
- KRAS_SIGNALING_DN-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 2ad90ba0-8038-4bad-afa3-d176f63b42f0 | — | — | 0.917 |
| 2 | 992ce1bc-46a2-4f57-ac7a-c6368c69c67c | — | — | 0.915 |
| 3 | TCGA-38-4625-01A-01R-1206-07 | — | cohortA1 | 0.895 |
| 4 | ddd65fce-1a39-415c-9114-7a9c8e9b266c | — | — | 0.882 |
| 5 | ERR2208906 | — | — | 0.882 |
| 6 | 1e0f16e6-de1c-4d1e-b1f6-5fabbea1591b | — | — | 0.875 |
| 7 | 5ffcc7c5-661f-4eed-b5e6-ed158c668321 | — | — | 0.874 |
| 8 | f66a9fee-f63a-4398-b242-9c065bbe213d | — | — | 0.873 |
| 9 | SRR6013496 | — | cohortA4 | 0.870 |
| 10 | 46E565A7-5022-4648-9035-B60FC7CFD6E7 | — | — | 0.870 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.640 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.520 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.480 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.410 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.410 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.410 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.360 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.350 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.310 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.290 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.270 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.250 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.240 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.240 | Inavolisib | — uncovered |
| PEROXISOME | 0.240 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.230 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.170 | Remibrutinib | — uncovered |